Marie-Claude C Hofmann, Ph.D.
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Endocrine Neoplasia and Hormonal Disorders - Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Endocrine Neoplasia and Hormonal Disorders - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1988 | Dept. of Oncology University Hospital Zürich, Dept. of Biology University of Lausanne, Lausanne, CH, Cell Biology, Cancer Research, Ph.D |
| 1977 | Dept. of Biology University of Lausanne, Lausanne, CH, Biological Sciences, BS |
Postgraduate Training
| 1991-1995 | Postdoctoral Fellowship, NRSA, Developmental and Reproductive Biology, Sanford-Burnham Medical Discovery Institute, La Jolla, California |
| 1990-1991 | Postdoctoral Fellowship, Swiss Foundation for Medical and Biological Research, Developmental and Reproductive Biology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA |
| 1989-1991 | Postdoctoral Fellowship, Swiss National Foundation for Scientific Research, Developmental and Reproductive Biology, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA |
| 1988-1989 | Postdoctoral Fellowship, Cancer Research, Urology, University of Zürich Medical School, Zürich |
| 1987-1988 | Predoctoral Fellowship, Swiss Anti-Cancer League, Cancer Research, Hematology, University Hospital Zürich, Zürich |
| 1983-1986 | Predoctoral Fellowship, Swiss National Foundation for Scientific Research, Cancer Research, Hematology, University Hospital Zürich, Zürich |
Experience & Service
Academic Appointments
Associate Professor, Department of Comparative Biosciences, University of Illinois at Urbana-Champaign, Urbana-Champaign, IL, 2006 - 2012
Associate Professor, Department of Biology, University of Dayton, Dayton, OH, 2001 - 2006
Assistant Professor, Department of Biology, University of Dayton, Dayton, OH, 1995 - 2001
Institutional Committee Activities
Chair, Research Grand Rounds Committee, Division of Internal Medicine Research Committee, 2021 - 2023
Chair, Research Committee, Division of Internal Medicine, Research Committee, 2017 - 2019
Member, IACUC, 2015 - 2018
Deputy Chair, Research Committee, Division of Internal Medicine Research Committee, 2015 - 2017
Ad Hoc Member, Faculty Search Committees, Department of Endocrine Neoplasia & HD, 2015 - Present
Member, Human Stem Cell Research Committee, 2015 - Present
Faculty, Teaching Faculty, GSBS Graduate Faculty, 2014 - Present
Member, Departmental Executive Committee, Endocrine Neoplasia & HD, 2014 - Present
Senator, Faculty Senate, 2014 - 2019
Member, Faculty Academic Review Committee, 2014 - 2018
Member, Division of Internal Medicine, Research Committee, 2013 - Present
Co-Chair, Departmental Seminar Series, Endocrine Neoplasia & HD, 2012 - 2015
Member, Institutional Research Grant Program Committee (IRG), 2012 - Present
Chair, Division of Cell Biology and Anatomy, Comparative Biosciences, 2011 - 2012
Member, Department Executive Committee, Comparative Biosciences, 2011 - 2012
Member, Safety Committee, College of Veterinary Medicine, 2011 - 2012
Member, Interviewer, Veterinary Medicine Admission Committee, College of Veterinary Medicine, 2011 - 2012
Member, Physiology Search Committee, Comparative Biosciences, 2011 - 2011
Member, Histology Search Committee, Comparative Biosciences, 2010 - 2010
Member, Compliance Advisory Committee, 2009 - 2012
Member, Grievance Committee, College of Veterinary Medicine, 2009 - 2012
Chair, Safety Committee, Comparative Biosciences, 2008 - 2012
Mentor (3 Faculties), Junior Faculty Mentoring Committee, Comparative Biosciences, 2007 - 2012
Member, Equal Employment Opportunities, Comparative Biosciences, 2007 - 2012
Member, Research Advisory Committee, College of Veterinary Medicine, 2007 - 2012
Chair, Promotion & Tenure Committee, College of Arts & Sciences, 2005 - 2006
Chair, Physiology/Cell Biology Search Committee, Biology Department, 2004 - 2005
Member, Promotion & Tenure Committee, College of Arts & Sciences, 2002 - 2005
Member, Graduate Curriculum Assessment, Biology Department, 2001 - 2006
Member, Genetics Search Committee, Biology Department, 2000 - 2001
Member, Safety Committee, 1999 - 2006
Chair, Safety Committee, Biology Department, 1999 - 2006
Member, Undergraduate Recruitment, Biology Department, 1999 - 2006
Chair, Physiology Search Committee, Biology Department, 1998 - 2000
Member, Interviewer, Joint Admission to U Cincinnati Medical School Program (JAMS) Selection Committee, 1998 - 2005
Member, Central (Roesh) Library Committee, 1998 - 2004
Chair, Distinguished Speaker Series, Biology Department, 1997 - 1998
Member, Premedical/Predental Advisor, Premedical/Predental Faculty Committee, College of Arts & Sciences,, 1997 - 2006
Member, Graduate Admissions, Biology Department, 1997 - 1999
Member, Graduate Coordinating and Assessment Committee, Department of Biology, 1996 - 1997
Chair, Library Liaison, Biology Department, 1996 - 2006
Member, Undergraduate Curriculum Assessment, Biology Department, 1995 - 2001
Member, Committee for the Development of Scientific Writing, Biology Department, 1995 - 1997
Honors & Awards
| 2024 | Distinguished Andrologist Award, American Society of Andrology |
| 2011 | Killam Visiting Research Scholar Award, University of Calgary, AB, Canada |
| 2010 | Dr. Gordon and Mrs. Helen Kruger Research Excellence Award, College of Veterinary Medicine, University of Illinois at Urbana-Champaign |
| 2007 | NIH Independent Scientist Award (K02 HD054607), NIH, NICHD |
| 2005 | George E. Nolan Award for Excellence in Research, University of Dayton, OH |
| 1993 | National Research Service Award, National Cancer Institute, USA, NIH, NCI |
Selected Publications
Peer-Reviewed Articles
- Houl JH, Bagheri-Yarmand R, Kunnimalaiyaan M, Parek PA, Chari N, McBeath E, Dadbin A, Henderson Y, Powell RT, Stephan C, Cabanillas ME, Lai SY, Dadu R, Zafereo M, Hofmann MC. Role of the ETV5/p38 Signaling Axis in BRAF-Mutated Anaplastic Thyroid Cancers. Molecular Cancer Therapeutics. e-Pub 2024.
- Iyer P, Hofmann MC, Ferrarotto R, Dadbin A, Gule-Monroe M, Williams M, Dadu R, Gunn GB, Busaidy NL, Wang JR, Zafereo M, Cabanillas ME. Neoadjuvant vemurafenib in patients with BRAF mutated, locally advanced papillary thyroid carcinoma. Thyroid. e-Pub 2024.
- Houl JH, Bagheri-Yarmand R, Dabin A, Miranda-Mendez P, Wang JR, Fraustro A, Hamidi S, Maniakas A, Iyer P, Busaidy NL, Dadu R, Lai SY, Zafereo M, Cabanillas ME, Hofmann MC. Targeting the MAPK and DNA Repair Pathways in Poorly Differentiated and Anaplastic Thyroid Cancer Cells. e-Pub 2024.
- Hicks HM, Pozdeyev N, Sams S, Pugazhenthi U, Bales ES, Hofmann MC, McKenna LR, Schweppe RE. Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. Molecular Cancer Research 21(9):867-880, 2023. e-Pub 2023. PMID: 37219859.
- Hamidi S, Hofmann MC, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. New Treatments for Advanced Differentiated Thyroid Cancers and Potential Mechanisms of Drug Resistance. Frontiers in Endocrinology 14, 2023. e-Pub 2023.
- Zhao X, Wang RJ, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia A, Diersing J, Gross N, Goepfert RP, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo M. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600EMutant Anaplastic Thyroid Cancer. Thyroid 33(4):484-491, 2023. e-Pub 2023. PMID: 36762947.
- Rose MM, Espinoza VL, Hoff KJ, Pike LA, Sharma V, Hofmann MC, Tan AC, Pozdeyev N, Schweppe RE. BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer. Cancers 15(2), 2023. e-Pub 2023. PMID: 36672327.
- Björndahl L, Barratt CLR, Mortimer D, Agarwal A, Aitken RJ, Alvarez JG, Aneck-Hahn N, Arver S, Baldi E, Bassas L, Boitrelle F, Bornman R, Carrell DT, Castilla JA, Cerezo Parra G, Check JH, Cuasnicu PS, Darney SP, de Jager C, De Jonge CJ, Drevet JR, Drobnis EZ, Du Plessis SS, Eisenberg ML, Esteves SC, Evgeni EA, Ferlin A, Garrido N, Giwercman A, Goovaerts IGF, Haugen TB, Henkel R, Henningsohn L, Hofmann MC, Hotaling JM, Jedrzejczak P, Jouannet P, Jørgensen N, Kirkman Brown JC, Krausz C, Kurpisz M, Kvist U, Lamb DJ, Levine H, Loveland KL, McLachlan RI, Mahran A, Maree L, Martins da Silva S, Mbizvo MT, Meinhardt A, Menkveld R, Mortimer ST, Moskovtsev S, Muller CH, Munuce MJ, Muratori M, Niederberger C, O'Flaherty C, Oliva R, Ombelet W, Pacey AA, Palladino MA, Ramasamy R, Ramos L, Rives N, Roldan ER, Rothmann S, Sakkas D, Salonia A, Sánchez-Pozo MC, Sapiro R, Schlatt S, Schlegel PN, Schuppe HC, Shah R, Skakkebæk NE, Teerds K, Toskin I, Tournaye H, Turek PJ, van der Horst G, Vazquez-Levin M, Wang C, Wetzels A, Zeginiadou T, Zini A. Standards in semen examination: publishing reproducible and reliable data based on high-quality methodology. Human Reproduction 37(11):2497-2502, 2022. e-Pub 2022.
- Henderson YC, Mohamed ASR, Maniakas A, Chen Y, Powell RT, Peng S, Cardenas M, Williams MD, Bell D, Zafereo ME, Wang RJ, Scherer SE, Wheeler DA, Cabanillas ME, Hofmann MC, Johnson FM, Stephan CC, Sandulache V, Lai SY. A High-Throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism 106(10):2962-2978, 2021. e-Pub 2021. PMID: 34120183.
- Bagheri-Yarmand R, Busaidy NL, Fujiwara E, Danysh BP, Evans KW, Moss T, Akcakanat A, Ng PS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, Shah MH, Ringel MD, Hofmann MC. Rac1 alterations induce acquired dabrafenib resistance in association with anaplastic transformation in a papillary thyroid cancer patient. Cancers 13(19), 2021. e-Pub 2021. PMID: 34638434.
- Maniakas A, Henderson YC, Hei H, Peng S, Chen Y, Jiang Y, Ji S, Cardenas M, Chiu Y, Bell D, Williams MD, Hofmann MC, Scherer SE, Wheeler DA, Busaidy NL, Dadu R, Wang JR, Cabanillas ME, Zafereo M, Johnson FM, Lai SY. Novel anaplastic thyroid cancer PDXs and cell lines: Expanding preclinical models of genetic diversity. J Clin Endocrinol Metab 106(11):e4652-e4665, 2021. e-Pub 2021. PMID: 34147031.
- Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid 31(8):1235-1243, 2021. e-Pub 2021. PMID: 33599171.
- Maniakas A, Dadu R, Busaidy NL, Wang RJ, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross N, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncology 6(9):1397-1404, 2020. e-Pub 2020. PMID: 32761153.
- Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired secondary RAS mutation in BRAFV600E -mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid 30(9):1288-1296, 2020. e-Pub 2020. PMID: 32216548.
- Fujiwara E, Parker-Thornburg J, Fujii Y, Aryal NK, Smith CN, Hofmann MC, Abe J, Fujiwara K. Rapid evaluation of CRISPR guides and donors for engineering mice. Genes 11(6):1-25, 2020. e-Pub 2020. PMID: 32521708.
- Parekh PA, Garcia TX, Waheeb R, Jain V, Gandhi P, Danysh B, Shetty G, Maeistrich M, Hofmann MC. Undifferentiated spermatogonia regulate postnatal expression of CYP26B1 through NOTCH signaling in Sertoli cells. FASEB J 33(7):8423-8435, 2019. e-Pub 2019. PMID: 30991836.
- Parekh P, Garcia TX, Hofmann MC. Regulation of GDNF expression in Sertoli cells. Reproduction 157(3):R95-R107, 2019. e-Pub 2019. PMID: 30620720.
- Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui JH, Williams MD, Hess KN, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME. Circulating BRAF V600E cell free DNA (cfDNA) as a biomarker in the management of Anaplastic Thyroid Carcinoma. JCO Precision Oncology 2:1-11, 2018. e-Pub 2018.
- Puli OR, Danysh BP, McBeal-Fujiwara EM, Sinha, DT, Koang J, Powell RT, Cabanillas ME, Cote GJ, Hofmann MC. The transcription factor ETV5 mediates BRAFV600E-induced proliferation and TWIST1 expression in papillary thyroid cancer cells. Neoplasia 20(11):1121-1134, 2018. e-Pub 2018. PMID: 30265861.
- Paez-Mayorga J, Kotla S, Tao Y, Giancursio C, Danysh BP, Hofmann MC, Le NT. Ponatinib activates an inflammatory response in endothelial cells via ERK5 SUMOylation. Front. Cardiovasc. Med 5:125, 2018. e-Pub 2018. PMID: 30238007.
- Cabanillas M, Ferrarotto R, Garden A, Ahmed S, Busaidy N, Dadu R, Williams M, Skinner H, Gunn B, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7):945-951, 2018. e-Pub 2018. PMID: 29742974.
- Beadnell TC, Wuensch KE, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Src Mediated Regulation of the PI3K Pathway in Advanced Papillary and Anaplastic Thyroid Cancer. Oncogenesis 17(2):23-36, 2018. e-Pub 2018. PMID: 29487290.
- Iyer PC, Cote G, Hai T, Gule-Monroe MK, Bui-Griffith J, Williams MD, Hess KR, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn GB, Skinner H, Garden AS, Cabanillas ME. Circulating BRAF V600E cell-free DNA as a biomarker in the management of anaplastic thyroid carcinoma. JCO Precision Oncology 2:1-11, 2018. e-Pub 2018. PMID: 35135166.
- Garcia TX, Parekh P, Gandhi P, Sinha K, Hofmann MC. The NOTCH ligand JAG1 regulates GDNF expression in Sertoli cells. Stem Cells & Development 26(8):585-598, 2017. e-Pub 2017. PMID: 28051360.
- Liang S, Yin L, Shengyang Yu K, Hofmann MC, and Yu X. High-Content Analysis Provides Mechanistic Insights into the Testicular Toxicity of Bisphenol A and Selected Analogues in Mouse Spermatogonial Cells. Toxicol Sci 155(1):43-60, 2017. e-Pub 2017. PMID: 27633978.
- Danysh BP, Rieger E, Sinha D, Cabanillas M, Cote G, Hofmann MC. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget 7(21):30907-30923, 2016. e-Pub 2016. PMID: 27127178.
- Garcia TX, Hofmann MC. Regulation of germ line stem cell homeostasis. Animal Reproduction 12(1):35-45, 2015. e-Pub 2015.
- Cote GJ, Grubbs EG, Hofmann MC. Thyroid C-Cell biology and Oncogenic Transformation. Recent Results Cancer Res 204:1-39, 2015. e-Pub 2015. PMID: 26494382.
- Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres V, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ, Hofmann MC, Verhaak R, Pagliaro L, Lee MH, Yeung SCJ, and Habra MA. Hepatocyte growth factor/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma: a potential therapeutic target. Cancer Research 75(19):4131-4142, 2015. e-Pub 2015. PMID: 26282167.
- Garcia TX, Farmaha JK, Kow S, Hofmann MC. RBPJ in mouse Sertoli cells is required for proper regulation of the testis stem cell niche. Development 141(23):4468-4478, 2014. e-Pub 2014. PMID: 25406395.
- Garcia TX, Costa GM, Franca LR, Hofmann MC. Sub-acute intravenous administration of silver nanoparticles in male mice alters Leydig cell function and testosterone levels. Reprod Toxicol 45(6):59-70, 2014. e-Pub 2014. PMID: 24447867.
- Hofmann MC. Stem cells and nanomaterials. Advances in experimental medicine and biology 811:255-275, 2014. e-Pub 2014. PMID: 24683036.
- Gabrielson NP, Desai AV, Mahadik B, Hofmann MC, Kenis PJ, Harley BA. Cell-Laden Hydrogels in Integrated Microfluidic Devices for Long-Term Cell Culture and Tubulogenesis Assays. Small 9(18):3076-81, 2013. e-Pub 2013. PMID: 23468408.
- Garcia TX, Hofmann MC. NOTCH signaling in Sertoli cells regulates gonocyte fate. Cell Cycle 12(16):2538-45, 2013. e-Pub 2013. PMID: 23907117.
- Garcia TX, DeFalco T, Capel B, Hofmann MC. Constitutive activation of NOTCH1 signaling in Sertoli cells causes gonocyte exit from quiescence. Dev Biol 377(1):188-201, 2013. e-Pub 2013. PMID: 23391689.
- Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C. Bone Metastases and Skeletal Related Events in Patients with Malignant Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 98(4):1492-7, 2013. e-Pub 2013. PMID: 23436918.
- Lucas BE, Fields C, Joshi N, Hofmann MC. Mono-(2-ethylhexyl)-phthalate (MEHP) affects ERK-dependent GDNF signaling in mouse stem-progenitor spermatogonia. Toxicology 299(1):10-9, 2012. e-Pub 2012. PMID: 22564763.
- Garcia T, Hofmann MC. Isolation of undifferentiated and early differentiating type A spermatogonia from Pou5f1-GFP reporter mice. Methods Mol Biol 825:31-44, 2012. e-Pub 2012. PMID: 22144234.
- Campos-Junior PH, Costa GM, Lacerda SM, Rezende-Neto JV, de Paula AM, Hofmann MC, de França LR. The spermatogonial stem cell niche in the collared peccary (Tayassu tajacu). Biol Reprod 86(5):155, 1-10, 2012. e-Pub 2012. PMID: 22262689.
- Costa GM, Avelar GF, Rezende-Neto JV, Campos-Junior PH, Lacerda SM, Andrade BS, Thomé RG, Hofmann MC, Franca LR. Spermatogonial stem cell markers and niche in equids. PLoS One 7(8):e44091, 2012. e-Pub 2012. PMID: 22937157.
- Simon L, Ekman GC, Garcia T, Carnes K, Zhang Z, Murphy T, Murphy KM, Hess RA, Cooke PS, Hofmann MC. ETV5 regulates sertoli cell chemokines involved in mouse stem/progenitor spermatogonia maintenance. Stem Cells 28(10):1882-92, 2010. e-Pub 2010. PMID: 20799334.
- Braydich-Stolle LK, Lucas B, Schrand A, Murdock RC, Lee T, Schlager JJ, Hussain SM, Hofmann MC. Silver nanoparticles disrupt GDNF/Fyn kinase signaling in spermatogonial stem cells. Toxicol Sci 116(2):577-89, 2010. e-Pub 2010. PMID: 20488942.
- Kokkinaki M, Lee TL, He Z, Jiang J, Golestaneh N, Hofmann MC, Chan WY, Dym M. Age affects gene expression in mouse spermatogonial stem/progenitor cells. Reproduction 139(6):1011-20, 2010. e-Pub 2010. PMID: 20371641.
- Morrow CM, Tyagi G, Simon L, Carnes K, Murphy KM, Cooke PS, Hofmann MC, Hess RA. Claudin 5 expression in mouse seminiferous epithelium is dependent upon the transcription factor ets variant 5 and contributes to blood-testis barrier function. Biol Reprod 81(5):871-9, 2009. e-Pub 2009. PMID: 19571261.
- Tyagi G, Carnes K, Morrow C, Kostereva NV, Ekman GC, Meling DD, Hostetler C, Griswold M, Murphy KM, Hess RA, Hofmann MC, Cooke PS. Loss of Etv5 decreases proliferation and RET levels in neonatal mouse testicular germ cells and causes an abnormal first wave of spermatogenesis. Biol Reprod 81(2):258-66, 2009. e-Pub 2009. PMID: 19369650.
- Simon L, Ekman GC, Kostereva N, Zhang Z, Hess RA, Hofmann MC, Cooke PS. Direct transdifferentiation of stem/progenitor spermatogonia into reproductive and nonreproductive tissues of all germ layers. Stem Cells 27(7):1666-75, 2009. e-Pub 2009. PMID: 19544441.
- Kokkinaki M, Lee TL, He Z, Jiang J, Golestaneh N, Hofmann MC, Chan WY, Dym M. The molecular signature of spermatogonial stem/progenitor cells in the 6-day-old mouse testis. Biol Reprod 80(4):707-17, 2009. e-Pub 2009. PMID: 19109221.
- Chu C, Schmidt JJ, Carnes K, Zhang Z, Kong HJ, Hofmann MC. Three-dimensional synthetic niche components to control germ cell proliferation. Tissue Eng Part A 15(2):255-62, 2009. e-Pub 2009. PMID: 18816170.
- Schlesser HN, Simon L, Hofmann MC, Murphy KM, Murphy T, Hess RA, Cooke PS. Effects of ETV5 (ets variant gene 5) on testis and body growth, time course of spermatogonial stem cell loss, and fertility in mice. Biol Reprod 78(3):483-9, 2008. e-Pub 2008. PMID: 18032421.
- He Z, Jiang J, Kokkinaki M, Golestaneh N, Hofmann MC, Dym M. Gdnf upregulates c-Fos transcription via the Ras/Erk1/2 pathway to promote mouse spermatogonial stem cell proliferation. Stem Cells 26(1):266-78, 2008. e-Pub 2008. PMID: 17962702.
- He Z, Jiang J, Hofmann MC, Dym M. Gfra1 silencing in mouse spermatogonial stem cells results in their differentiation via the inactivation of RET tyrosine kinase. Biol Reprod 77(4):723-33, 2007. e-Pub 2007. PMID: 17625109.
- Braydich-Stolle L, Kostereva N, Dym M, Hofmann MC. Role of Src family kinases and N-Myc in spermatogonial stem cell proliferation. Dev Biol 304(1):34-45, 2007. e-Pub 2007. PMID: 17222400.
- Braydich-Stolle L, Nolan C, Dym M, Hofmann MC. Role of glial cell line-derived neurotrophic factor in germ-line stem cell fate. Ann N Y Acad Sci 1061:94-9, 2005. e-Pub 2005. PMID: 16467260.
- Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci 88(2):412-9, 2005. e-Pub 2005. PMID: 16014736.
- Chen C, Ouyang W, Grigura V, Zhou Q, Carnes K, Lim H, Zhao GQ, Arber S, Kurpios N, Murphy TL, Cheng AM, Hassell JA, Chandrashekar V, Hofmann MC, Hess RA, Murphy KM. ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature 436(7053):1030-4, 2005. e-Pub 2005. PMID: 16107850.
- Hofmann MC, Braydich-Stolle L, Dym M. Isolation of male germ-line stem cells; influence of GDNF. Dev Biol 279(1):114-24, 2005. e-Pub 2005. PMID: 15708562.
- Hofmann MC, Braydich-Stolle L, Dettin L, Johnson E, Dym M. Immortalization of mouse germ line stem cells. Stem Cells 23(2):200-10, 2005. e-Pub 2005. PMID: 15671143.
- Dettin L, Ravindranath N, Hofmann MC, Dym M. Morphological characterization of the spermatogonial subtypes in the neonatal mouse testis. Biol Reprod 69(5):1565-71, 2003. e-Pub 2003. PMID: 12855601.
- Hofmann MC, Van Der Wee KS, Dargart JL, Dirami G, Dettin L, Dym M. Establishment and characterization of neonatal mouse sertoli cell lines. J Androl 24(1):120-30, 2003. e-Pub 2003. PMID: 12514093.
- van der Wee KS, Johnson EW, Dirami G, Dym TM, Hofmann MC. Immunomagnetic isolation and long-term culture of mouse type A spermatogonia. J Androl 22(4):696-704, 2001. e-Pub 2001. PMID: 11451367.
- Billotte WG, Dumas K, Hofmann MC. Transcriptional pathways induced by fluid shear stress in mouse preosteoblast cells. Biomed Sci Instrum 37:1-6, 2001. e-Pub 2001. PMID: 11347369.
- van der Wee K, Hofmann MC. An in vitro tubule assay identifies HGF as a morphogen for the formation of seminiferous tubules in the postnatal mouse testis. Exp Cell Res 252(1):175-85, 1999. e-Pub 1999. PMID: 10502410.
- Encina NR, Billotte WG, Hofmann MC. Immunomagnetic isolation of osteoprogenitors from human bone marrow stroma. Lab Invest 79(4):449-57, 1999. e-Pub 1999. PMID: 10211997.
- Billotte WG, Hofmann MC. Establishment of a shear stress protocol to study the mechanosensitivity of human primary osteogenic cells in vitro. Biomed Sci Instrum 35:327-32, 1999. e-Pub 1999. PMID: 11143372.
- Hofmann MC, Millan JL. Establishment of Mammalian Testicular Cell Lines. Methods Cell Biol 57:93-10, 1998. e-Pub 1998. PMID: 9648101.
- Wolkowicz MJ, Coonrod SA, Reddi PP, Millan JL, Hofmann MC, Herr JC, Coonrod SM. Refinement of the differentiated phenotype of the spermatogenic cell line GC-2spd(ts). Biol Reprod 55(4):923-32, 1996. e-Pub 1996. PMID: 8879510.
- Hofmann MC, Abramian D, Millán JL. A haploid and a diploid cell coexist in an in vitro immortalized spermatogenic cell line. Dev Genet 16(2):119-27, 1995. e-Pub 1995. PMID: 7736662.
- Hofmann MC, Hess RA, Goldberg E, Millán JL. Immortalized germ cells undergo meiosis in vitro. Proc Natl Acad Sci U S A 91(12):5533-7, 1994. e-Pub 1994. PMID: 8202522.
- Cooker LA, Brooke CD, Kumari M, Hofmann MC, Millán JL, Goldberg E. Genomic structure and promoter activity of the human testis lactate dehydrogenase gene. Biol Reprod 48(6):1309-19, 1993. e-Pub 1993. PMID: 8318584.
- Narisawa S, Hofmann MC, Ziomek CA, Millán JL. Embryonic alkaline phosphatase is expressed at M-phase in the spermatogenic lineage of the mouse. Development 116(1):159-65, 1992. e-Pub 1992. PMID: 1483384.
- Hofmann MC, Narisawa S, Hess RA, Millán JL. Immortalization of germ cells and somatic testicular cells using the SV40 large T antigen. Exp Cell Res 201(2):417-35, 1992. e-Pub 1992. PMID: 1322317.
- Walt H, Emmerich P, Cremer T, Hofmann MC, Bannwart F. Supernumerary chromosome 1 in interphase nuclei of atypical germ cells in paraffin-embedded human seminiferous tubules. Lab Invest 61(5):527-31, 1989. e-Pub 1989. PMID: 2811300.
- Hofmann MC, Jeltsch W, Brecher J, Walt H. Alkaline phosphatase isozymes in human testicular germ cell tumors, their precancerous stage, and three related cell lines. Cancer Res 49(17):4696-700, 1989. e-Pub 1989. PMID: 2547514.
- Emmerich P, Jauch A, Hofmann MC, Cremer T, Walt H. Interphase cytogenetics in paraffin embedded sections from human testicular germ cell tumor xenografts and in corresponding cultured cells. Lab Invest 61(2):235-42, 1989. e-Pub 1989. PMID: 2755080.
- Bagheri-Yarmand R, McBeath E, Cruz L, Jimenez X, Ringel M, Hofmann MC. Role of the small GTPase RAC1 P34R mutation in cell division aberrations in anaplastic thyroid cancer. Cancer Letters.
Other Articles
- Cabanillas ME, Hofmann MC, Maniakas A, Hamidi S, Iyer P, Wang JR, Banuchi V, Ning MS, Spiotto MT, Gunn B, Lee A, Busaidy N, Dadu R, Lai SY, Zafereo M Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure. Thyroid.
- Fujiwara E, Fujiwara K, Hofmann MC Evidence-Based Guide to Using Artificial Introns for Tissue-Specific Knockout in Mice. International journal of molecular sciences 24(12), 2023. PMID: 37373404.
- Hamidi, S, Hofmann, M, Iyer, PC, Cabanillas, ME, Hu, MI, Busaidy, NL, Dadu, R New treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Frontiers in Endocrinology 14, 2023. PMID: 37435488.
- Hofmann MC, Kunnimalaiyaan M, Wang RJ, Busaidy NL, Sherman SI, Lai SY, Zafereo M, Cabanillas ME Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocrine-related cancer 29(11):R173-R190, 2022. PMID: 35975971.
- Björndahl, L, Barratt, CL, Mortimer, D, Agarwal, A, Aitken, RJ, Alvarez, JG, Aneck-Hahn, N, Arver, S, Baldi, E, Bassas, L, Boitrelle, F, Bornman, R, Carrell, DT, Castilla, JA, Parra, GC, Check, JH, Cuasnicu, PS, Darney, SP, de Jager, C, De Jonge, CJ, Drevet, JR, Drobnis, EZ, Du Plessis, SS, Eisenberg, ML, Esteves, SC, Evgeni, EA, Ferlin, A, Garrido, N, Giwercman, A, Goovaerts, IG, Haugen, TB, Henkel, R, Henningsohn, L, Hofmann, M, Hotaling, JM, Jedrzejczak, P, Jouannet, P, Jørgensen, N, Kirkman Brown, JC, Krausz, C, Kurpisz, M, Kvist, U, Lamb, DJ, Levine, H, Loveland, KL, McLachlan, RI, Mahran, A, Maree, L, da Silva, SM, Mbizvo, MT, Meinhardt, A, Menkveld, R, Mortimer, ST, Moskovtsev, S, Muller, CH, José Munuce, M, Muratori, M, Niederberger, CS, O’Flaherty, C, Oliva, R, Ombelet, W, Pacey, AA, Palladino, MA, Ramasamy, R, Ramos, L, Rives, N, Rs Roldan, E, Rothmann, SA, Sakkas, D, Salonia, A, Sánchez-Pozo, MC, Sapiro, R, Schlatt, S, Schlegel, PN, Schuppe, HC, Shah, R, Skakkebæk, N, Teerds, K, Toskin, I, Tournaye, H, Turek, PJ, van der Horst, G, Vazquez-Levin, M, Wang, C, Wetzels, A, Zeginiadou, T, Zini, A Standards in semen examination. Human Reproduction 37(11):2497-2502, 2022. PMID: 36112046.
- Rajpert-De Meyts E, Carrell DT, Simoni M, Giwercman A, Hofmann MC Marking the first decade of Andrology—Conception and early development of the journal. Andrology 10(S2):139-143, 2022. PMID: 36217711.
- Hofmann MC, Giwercman A Andrology and humanities. Andrology 10(5):823-824, 2022. PMID: 35763405.
- Hofmann MC, Fujiwara E Sertoli Cell-Germ Cell Interactions Within the Niche. Frontiers in Endocrinology 13, 2022. PMID: 35757413.
- França LR, Hess RA, Dufour JM, Hofmann MC, Griswold MD The Sertoli cell: one hundred fifty years of beauty and plasticity. Andrology 4(2):189-212, 2016. PMID: 26846984.
- Waheeb R, Hofmann MC Human spermatogonial stem cells: a possible origin for spermatocytic seminoma. Int J Androl 34(4 Pt 2):e296-305; discussion e305, 2011. PMID: 21790653.
- Lucas B, Fields C, Hofmann MC Signaling pathways in spermatogonial stem cells and their disruption by toxicants. Birth Defects Res C Embryo Today 87(1):35-42, 2009. PMID: 19306349.
- Liu CF, Barsoum I, Gupta R, Hofmann MC, Yao HH Stem cell potential of the mammalian gonad. Front Biosci (Elite Ed) 1:510-8, 2009. PMID: 19482665.
- Kostereva N, Hofmann MC Regulation of the spermatogonial stem cell niche. Reprod Domest Anim 43 Suppl 2:386-92, 2008. PMID: 18638151.
- Hofmann MC Gdnf signaling pathways within the mammalian spermatogonial stem cell niche. Mol Cell Endocrinol 288(1-2):95-103, 2008. PMID: 18485583.
- Morrow CM, Hostetler CE, Griswold MD, Hofmann MC, Murphy KM, Cooke PS, Hess RA ETV5 is required for continuous spermatogenesis in adult mice and may mediate blood testes barrier function and testicular immune privilege. Ann N Y Acad Sci 1120:144-51, 2007. PMID: 17911411.
- Hess RA, Cooke PS, Hofmann MC, Murphy KM Mechanistic insights into the regulation of the spermatogonial stem cell niche. Cell Cycle 5(11):1164-70, 2006. PMID: 16721062.
- Tsonis PA, Del Rio-Tsonis K, Wallace JL, Burns JC, Hofmann MC, Millan JL, Washabaugh CH Can insights into urodele limb regeneration be achieved with cell cultures and retroviruses?. Int J Dev Biol 40(4):813-6, 1996. PMID: 8877455.
- Hofmann MC, Millán JL Developmental expression of alkaline phosphatase genes; reexpression in germ cell tumours and in vitro immortalized germ cells. Eur Urol 23(1):38-44; discussion 45, 1993. PMID: 8386657.
Editorials
- Hofmann MC, Giwercman A. Toward standardization in reporting data on basic human semen examination. Andrology 11(7):1223-1224, 2023. PMID: 37740520.
- Giwercman, A, Hofmann, M. Editorial. Andrology 11(6):953, 2023. PMID: 37545352.
- Giwercman, A, Hofmann, M. Editorial. Andrology 10(8):1459, 2022. PMID: 36250392.
- Hofmann MC, Simoni M. Andrology Awards 2019 and 2020. Andrology 9(4):1025-1026, 2021. PMID: 34311501.
- Simoni M, Hofmann MC. The COVID-19 pandemics: shall we expect andrological consequences? A call for contributions to ANDROLOGY. Andrology 8(3):1, 2020. PMID: 32302464.
Book Chapters
- Bagheri-Yarmand R, Grubbs EG, Hofmann MC. Thyroid C-Cell Biology and Oncogenic Transformation. In: Medullary Thyroid Carcinoma Biology – Management – Treatment. Springer, 2025.
- Iyer, PC, Srour, S, Hofmann, M, Cabanillas, ME. Current Trends in Treatment and New Generation of Trials in Thyroid Cancer. In: Practical Management of Thyroid Cancer. Springer, 307-324, 2024.
- Cabanillas ME, Schweppe RE, Dadu R, Cote G, Beadnell TC, Hofmann MC. Translational Research and Genomics Driven Trials in Thyroid Cancer. In: Practical Management of Thyroid Cancer. Springer, 319-338, 2018.
- Cabanillas ME, Schweppe RE, Dadu R, Cote GJ, Beadnell TC, Hofmann MC. Future Developments and Directions for Research in Thyroid Cancer. In: Practical Management of Thyroid Cancer: A Multidisciplinary Approach. 2. Springer, 319-338, 2017.
- Cote G, Bagheri-Yarmand R, Hofmann MC, Gagel RF. Molecular Mechanisms of Disease: The RET Proto-Oncogene. In: Medullary Thyroid Cancer. Springer International Publishing, 47-63, 2016.
- Hofmann MC. Stem Cells and Nanomaterials. In: Nanomaterial (Adv Exp Med Biol). Springer, 255-275, 2014.
- Simon L, Hofmann MC, Cooke P. Spermatogonial stem cells-an alternative of pluripotent stem cells for regenerative medicine. In: Tissue Regeneration. In Tech, 2011.
- Hofmann MC, Braydich-Stolle LK. Neurotrophic Factors in the Development of the Postnatal Male Germ Line. In: The Y Chromosome and Male Germ Cell Biology in Health and Diseases in the Post-Genomic Era. World Scientific Publishing, 149-184, 2007.
- Hofmann MC, Dym M. Long Term Cultures of Mammallian Spermatogonia. In: Sertoli Cell Biology. Academic Press, 449-470, 2005.
- Hofmann MC, Abramian D, Weissig H, Richardson LL, Millan JL. Establishment of meiotic germ cell lines and their use to study spermatogenesis in vitro. In: Cellular and Molecular Regulation of Testicular Cells. Springer Verlag, 45-64, 1996.
Selected Presentations & Talks
Local Presentations
- 2024. Targeting DNA damage recognition and repair in PDTC/ATC. Invited. Anaplastic Thyroid Cancer Research Retreat. Houston, TX, US.
- 2024. Role of p38/MAPK in Anaplastic Thyroid Cancer. Invited. Anaplastic Thyroid Cancer Research Day. Houston, TX, US.
- 2021. Generating a Phf21a-Floxed Mouse With a Novel DECAI CRISPR System to Study the Function of BHC80 in Development and Disease. Conference. 26th Texas Forum for Reproductive Sciences. Houston, Texas, US.
- 2019. Mechanisms of Resistance to Kinase Inhibitors in PTC/ATC: an Update. Conference. Aggressive Thyroid Cancers Program Grant Retreat. Houston, Texas, US.
- 2018. Role of BHC80/phf21a in the Spermatogonial Stem Cell Niche. Conference. Texas Forum for Reproductive Sciences. Houston, Texas, US.
- 2018. Mechanisms of resistance to kinase inhibitors in PDTC. Conference. Anaplastic Thyroid Cancer Research Retreat. Houston, Texas, US.
- 2017. BHC80 is a possible co-repressor of the Notch signaling pathway in mouse Sertoli cells. Conference. Texas Forum for Reproductive Sciences. Houston, Texas, US.
- 2016. Effect of cabozantinib on HGF/MET signaling in the testis. Conference. Texas Forum for Reproductive Sciences. Houston, Texas, US.
- 2016. Repression of GDNF transcription by Jag1/Notch signaling in Sertoli Cells. Conference. Texas Forum for Reproductive Sciences. Houston, Texas, US.
- 2016. ETV5, an ETS family Transcription Factor, Drives Proliferation and Epithelial-to Mesenchymal Transition in Papillary Thyroid Cancer. Conference. Division of Internal Medicine Research Retreat. Houston, Texas, US.
- 2016. Markers for Targeted Immunotherapy of Anaplastic Thyroid Cancer. Conference. Division of Internal Medicine Research Retreat. Houston, Texas, US.
- 2016. Long-term BRAF(V600E) inhibition results in a spontaneous KRAS(G12D) mutation and increased epithelial to mesenchymal transition (EMT) in papillary thyroid cancer cells (PTC). Conference. Division of Internal Medicine Research Retreat. Houston, Texas, US.
- 2015. Testis Stem Cells Signaling Pathways: A Readout for Toxicity of Tyrosine Kinase Inhibitors. Conference. Division of Internal Medicine Research Retreat. Houston, Texas, US.
- 2015. Effect of cabozantinib on HGF-MET signaling in the testis. Conference. Department of Internal Medicine Research Retreat. Houston, Texas, US.
- 2015. Acquired BRAF Inhibitor (BRAFi) Resistance Drives EMT in Papillary Thyroid Cancer (PTC). Conference. Division of Internal Medicine Research Retreat. Houston, Texas, US.
- 2015. Ablation of Rbpj rescues early pro-spermatogonia loss from ectopic activation of Notch signaling in mouse Sertoli cells. Conference. Texas Forum for Reproductive Sciences. Houston, Texas, US.
- 2015. Regulation of male germ line stem cell homeostasis. Conference. Texas Forum for the Reproductive Sciences. Houston, Texas, US.
- 2015. Physical interaction between spermatogonial stem cells and Sertoli cells is required for control of germ cell numbers. Conference. Texas Forum for Reproductive Sciences. Houston, Texas, US.
- 2014. Role of ETV5 Transcription Factor in Mouse Thyroid Development. Conference. Rice Undergraduate Research Symposium. Houston, Texas, US.
- 2014. Juxtacrine signaling in the testis stem cell niche. Conference. Center for Reproductive Medicine, Reproductive Health Research Day. Houston, Texas, US.
- 2013. Generation of capillary-like structures from mouse primary spermatogonial stem cells in defined three dimensional collagen gels. Conference. Division of Internal Medicine Research Retreat. Houston, Texas, US.
- 2013. Effects of activated estrogen receptors on acquired BRAF inhibitor resistance in papillary thyroid cancer (PTC). Conference. Division of Internal Medicine Research Retreat. Houston, Texas, US.
- 2013. Disruption of NOTCH signaling in Sertoli cells induces testicular germ cell hyperplasia. Conference. Division of Internal Medicine Research Retreat. Houston, Texas, US.
- 2013. The extracellular matrix protein NOV mediates vasculogenesis from mouse primary spermatogonial stem cells. Conference. Texas Forum for Reproductive Sciences (TFRS). Houston, Texas, US.
Regional Presentations
- 2014. Rbpj is required in Sertoli cells for proper stem cell regulation. Conference. Texas Forum for Reproductive Sciences (TFRS). San Antonio, Texas, US.
- 2012. MEHP impairs spermatogonial stem cell self-renewal. Conference. Illinois Symposium for Reproductive Sciences (ISRS 2012). Chicago, IL, US.
- 2011. MEHP reduces Fos expression in freshly isolated spermatogonial stem cells. Conference. Illinois Symposium in Reproductive Sciences (ISRS2011). Urbana, IL, US.
- 2011. Notch signaling in fetal Sertoli cells regulates gonocyte differentiation. Conference. Illinois Symposium in Reproductive Sciences (ISRS2011). Urbana, IL, US.
- 2011. In vitro differentiation of mouse primary spermatogonial stem cells into endothelial cells using growth factors and novel extracellular matrix proteins in a three-dimensional collagen gel. Conference. Illinois Symposium in Reproductive Sciences (ISRS2011). Urbana, IL, US.
- 2009. The role of Notch signaling in the self-renewal and differentiation fate of mouse spermatogonial stem cells. Conference. 30th Annual Northwestern Mini-Symposium on Reproductive Biology. Evanston, IL, US.
- 2009. Isolation, characterization, and culture of canine spermatogonial stem cells. Conference. 30th Annual Northwestern Mini-Symposium on Reproductive Biology. Evanston, IL, US.
- 2009. Isolation and characterization of canine spermatogonial stem cells. Conference. Institute for Genomic Biology Annual Symposium. Urbana, IL, US.
- 2009. The transcription factor Etv5 regulates Sertoli cell chemokines involved in maintaining spermatogonial stem cells in the niche. Conference. Institute for Genomic Biology Annual Symposium. Urbana, IL, US.
- 2008. Phthalates decrease spermatogonial stem cell proliferation by altering GDNF signaling. Conference. 29th Annual Northwestern Mini-Symposium on Reproductive Biology. Evanston, IL, US.
- 2008. Update on Stem Cell Research for Human Diseases. Conference. Lions Club. Champaign, IL, US.
- 2008. Trans-differentiation of spermatogonial stem cells into reproductive and non-reproductive tissues of all three germ layers. Conference. 29th Annual Northwestern Mini-Symposium on Reproductive Biology. Evanston, US.
- 2008. Identification of determinants involved in vascular trans-differentiation of spermatogonial stem cells. Conference. 21st Cell and Molecular Biology & Molecular Biophysics Symposium (MCB-MB). Urbana, IL, US.
- 2007. Signaling Pathways within the Spermatogonial Stem Cell Niche. Conference. Biennial Reproductive Biology Retreat. Allerton, IL, US.
- 2007. Regulation of p53 expression in spermatogonia by Notch1/Jagged1 in vitro. Conference. 28th Annual Northwestern Symposium on Reproductive Biology. Evanston, IL, US.
- 2007. In Vitro Vasculogenesis in Tri-Dimensional Synthetic Niches. Conference. Institute for Genomic Biology. Urbana, IL, US.
- 2006. Transplantation of immortalized germ cells. Conference. Ohio Academy of Sciences Annual Meeting. Dayton, OH, US.
- 2006. Effects of functionalized TiO2 nanoparticles on cellular apoptosis and formation of reactive oxygen species. Conference. Ohio Academy of Sciences Annual Meeting. Dayton, OH, US.
- 2006. Differential expression of molecular markers during osteogenesis in vivo. Conference. Ohio Academy of Sciences Annual Meeting. Dayton, OH, US.
National Presentations
- 2024. Site-Specific HRAS Q61R Activation Promotes Cell Proliferation via Activation of the PI3kinase/AKT/mTOR Pathway and TP53 Inactivation in Medullary Thyroid Cancer. Conference. Chicago, IL, US.
- 2024. Anaplastic Thyroid Cancer Bone Metastasis: Mechanistic Insight From Mouse Models. Invited. Chicago, IL, US.
- 2024. Clinicopathological Features of Advanced, RAS-driven Differentiated Thyroid Carcinoma (DTC). Conference. Chicago, IL, US.
- 2024. Characterization of RAS-mutant Anaplastic Thyroid Carcinoma (ATC). Conference. Chicago, IL, US.
- 2024. Role of the ETV5/p38 Signaling Axis in BRAF-Mutated Anaplastic Thyroid Cancers. Conference. Chicago, IL, US.
- 2024. Targeting the MAPK and DNA Repair Pathways in Poorly Differentiated and Anaplastic Thyroid Cancer Cells. Conference. Chicago, IL, US.
- 2024. Role of p38/MAPK in Aggressive Thyroid Cancers. Conference. Boston, MA, US.
- 2023. Evidence-Based Guide to Using Artificial Introns for Tissue-Specific Knockout in Mice. Conference. Boston, MA, US.
- 2023. Role of LSD1 in Mouse Sertoli Cells. Conference. Boston, MA, US.
- 2022. Disruption of Cell Division by P34R Mutated RAC1. Conference. Washington, DC, US.
- 2021. RAC1 induces acquired dabrafenib resistance in association with anaplastic transformation in a papillary thyroid cancer patient. Conference. Virtual Meeting, US.
- 2021. Novel in Vitro Targeted Combination Therapies for Anaplastic Thyroid Cancer. Conference. Virtual Meeting, US.
- 2020. Increased donor DNA sequence integration by CRISPR/Cas9 in mice: Mechanistic insights. Conference. Virtual Meeting, US.
- 2020. Generation of a Phf21a-Floxed Mouse Using a Novel DECAI CRISPR Method. Conference. Virtual Meeting, US.
- 2019. Tissue-Specific Knockout of Genes in Mice Using DECAI CRISPR. Conference. Washington, DC, US.
- 2019. Revolutionizing the therapeutic landscape of a deadly disease. Conference. Chicago, IL, US.
- 2019. An acquired novel Rac1P34R mutation drives proliferation and actin reorganization in papillary thyroid cancer cells. Conference. Chicago, IL, US.
- 2019. How to Advocate for Ourselves. Conference. Chicago, IL, US.
- 2019. Regulation of blood-testis barrier proteins through NOTCH non-canonical pathways. Conference. Chicago, IL, US.
- 2019. Preclinical Modeling of BRAF Inhibitor Resistance Mechanisms in Thyroid Cancer. Conference. New Orleans, LA, US.
- 2018. Rapidly increasing knock-in efficiency of CRISPR in mice by using blastocysts as a testing model. Conference. San Diego, CA, US.
- 2018. Mechanisms of Resistance to Kinase Inhibitors in PTC and ATC. Conference. Washington, DC, US.
- 2018. Novel Mechanisms of Resistance to Kinase Inhibitors in PTC. Conference. Rockville, MD, US.
- 2018. BHC80 is a Co-Repressor of NOTCH/RBPJ Signaling in Sertoli Cells. Conference. New Orleans, LA, US.
- 2018. From Post-Doc to Assistant Professor. Conference. Portland, OR, US.
- 2018. Doing Basic Research in a Clinical World. Conference. Portland, OR, US.
- 2017. The Chromatin Modifier Cofactor BHC80 is a Downregulator of Notch Signaling in Sertoli cells. Conference. Kona, HI, US.
- 2017. Regulation of Cyp25B1 expression in the mammalian testis. Conference. Miami, FL, US.
- 2017. The chromatin modifier BHC80 is a downregulator of NOTCH signaling in the mammalian testis. Conference. Miami, FL, US.
- 2017. Regulation of Cyp26B1 expression in the spermatogonial stem cell niche. Conference. Miami, FL, US.
- 2016. Long-term BRAF(V600E) inhibition results in a spontaneous KRAS(G12D) mutation and increased epithelial to mesenchymal transition (EMT) in papillary thyroid cancer cells (PTC). Conference. New Orleans, LA, US.
- 2016. Activation of NOTCH signaling in Sertoli cells in vivo is dependent upon the presence of germ cells. Conference. New Orleans, LA, US.
- 2016. Ablation of Rbpj rescues early pro-spermatogonia loss from ectopic activation of Notch signaling in mouse Sertoli cells. Conference. New Orleans, LA, US.
- 2016. The JAG1/NOTCH canonical effectors HES1 and HEY1 bind to the GDNF proximal promoter to repress its transcription in Sertoli cells. Conference. New Orleans, LA, US.
- 2016. Using Immunodetection Techniques for Assessing Male Fertility. Conference. New Orleans, LA, US.
- 2015. A Spontaneous KRAS(G12D) Mutation Following Long-Term Vemurafenib Treatment Drives Acquired BRAF Inhibitor (BRAFi) Resistance in a BRAF(V600E) PTC Cell Line. Conference. Orlando, FL, US.
- 2015. ETV5, an Ets Transcription Factor, is a Marker for Thyroid Cancer Progression. Conference. Orlando, FL, US.
- 2015. NOTCH Signaling in Sertoli Cells. Conference. Salt Lake City, UT, UT, US.
- 2014. Improving Sperm Output in Oligospermia?. Conference. Grand Case.
- 2014. NOTCH signaling regulates the testis stem cell niche. Conference. New London, NH, US.
- 2014. Notch Signaling in the Male Germ Line Stem Cell Niche. Conference. Chicago, IL, US.
- 2012. Generation of capillary-like structures from mouse primary spermatogonial stem cells in defined three-dimensional collagen gels. Conference. State College, PA, US.
- 2012. Silver nanoparticles affect Leydig cell function in vivo. Conference. Houston, TX, US.
- 2012. MEHP reduces maintenance and proliferation of primary spermatogonial stem cells in vitro. Conference. Tucson, AZ, US.
- 2012. Constitutive expression of activated NOTCH1 in Sertoli cells leads to a loss of GDNF and CYP26B1 expression, and premature gonocyte differentiation. Conference. Tucson, AZ, US.
- 2012. Intravenous administration of silver nanoparticles in male mice alters Leydig cell function and increases serum testosterone, but does not perturb spermatogenesis. Conference. San Francisco, CA, US.
- 2011. Overactivation of Notch signaling in fetal Sertoli cells results in dysregulation of germ cells, which results in germ cell apoptosis and Sertoli-only phenotype. Conference. Portland, OR, US.
- 2011. Notch signaling in the postnatal male germ-line. Conference. Portland, OR, US.
- 2010. Characterization of Ubiquitin Carboxyl-terminal Hydrolase L1 in the Fate Determination of Spermatogonia. Conference. Milwaukee, WI, US.
- 2010. Differentiation of stem/progenitor spermatogonia into prostatic epithelium: direct or indirect?. Conference. Milwaukee, WI, US.
- 2010. Spermatogonial stem cell isolation, culture, and analysis in vitro. Conference. Houston, TX, US.
- 2010. Reporter mice for stem cell isolation. Conference. Houston, TX, US.
- 2010. MEHP decrease spermatogonial stem cell proliferation by altering GDNF signaling. Conference. Salt Lake City, UT, US.
- 2009. Differentiation of Spermatogonial Stem Cells into Capillaries. Conference. St Croix.
- 2009. Phthalates decrease spermatogonial stem cell proliferation by altering GDNF signaling. Conference. Philadelphia, PA, US.
- 2009. Vascular trans-differentiation of spermatogonial stem cells. Conference. Philadelphia, PA, US.
- 2008. Synthetic stem cell niche for in vitro spermatogonial stem cell culture. Conference. Philadelphia, PA, US.
- 2008. Signal Integration Within the Spermatogonial Stem Cell Niche. Conference. Kailua-Kona, HI, US.
- 2008. Regulation of the Spermatogonial Stem cell Niche. Conference. Albuquerque, NM, US.
- 2008. Silver nanoparticles disrupt GDNF signaling in male germ-line stem cells. Conference. Seattle, WA, US.
- 2007. Isolation and characterization of GFRa-1 positive spermatogonial stem cells in the immature mouse. Conference. Washington, DC, US.
- 2007. Neonatal role of Ets-related molecule (ERM) in spermatogonial stem cell (SSC) maintenance may involve SSC receptors for GDNF. Conference. Tampa, FL, US.
- 2007. Regulation of apoptosis in spermatogonial stem cells by Jagged1 and GDNF in vitro. Conference. Tampa, FL, US.
- 2007. Time course of spermatogonial stem cell loss in ERM knockout mice: critical neonatal effects of ERM. Conference. Tampa, FL, US.
- 2007. Ets-related molecule (ERM) and spermatogonial stem cell self-renewal. Conference. Keystone, CO, US.
- 2006. Effects of Jagged1 and GDNF on mouse spermatogonial stem cells in vitro. Conference. Chicago, IL, US.
- 2006. GDNF signals through Src-dependent and Src-independent mechanisms in male germ-line stem cells. Conference. Chicago, IL, US.
- 2006. Effect of silver nanoparticles on Src activity in C18-4 cells. Conference. San Diego, CA, US.
- 2005. A germ-line stem cell line as a model for evaluating the cytotoxicity of nanoparticles in vitro. Conference. New Orleans, LA, US.
- 2004. Influence of GDNF on Spermatogonial Stem Cells. Conference. Washington, DC, US.
- 2004. Influence of Glial Cell Line-Derived Neurotrophic Factor (GDNF) on Male Germ Line Stem Cells. Conference. New London, CT, US.
- 2003. Isolation of testicular stem cells; influence of glial cell line-derived neurotrophic factor in vitro. Conference. Baltimore, MD, US.
- 2002. Microarray analysis of GDNF-responsive genes in type A spermatogonia. Conference. St Thomas, VI.
- 2001. Immunomagnetic Isolation of Germ Cells. Conference. Charlottesville, VA, US.
- 2000. In vitro Culture Systems for Male Germ Cells. Conference. Washington, DC, US.
- 1995. Establishment of Murine Meiotic Germ Cell Lines and Their Use to Study Spermatogenesis in vitro. Conference. Raleigh, NC, US.
International Presentations
- 2023. Evidence-Based Guide to Using Artificial Introns for Tissue-Specific Knockout in Mice. Conference. International Transgenic Technology Meeting. Houston, US.
- 2023. Resistance to Kinase Inhibitors in BRAF-Mutated Anaplastic Thyroid Cancer. Conference. Naples, IT.
- 2022. BRAF/MEK inhibitor combination therapy in BRAF V600E-mutated papillary thyroid carcinoma: Does the presence of a TERT promoter mutation influence therapeutic response?. Conference. Montreal, CA.
- 2022. Dedifferentiation of a Human Papillary Thyroid Tumor into Aggressive Anaplastic Thyroid Cancer Upon Dabrafenib Treatment: Pleiotropic Roles of the Small GTPase RAC1. Conference. Montreal, CA.
- 2022. Roles of BHC80/LSD1 in spermatogenesis. Conference. Nairobi, KE.
- 2020. Floxing Mice Using a Novel DECAI CRISPR System. Conference. Virtual Meeting, US.
- 2019. SED [Single strand Ended Double strand] DNA donors as an inexpensive, easy to make, and efficiently inserted, long CRISPR donor. Conference. Kobe, JP.
- 2018. An acquired novel RAC1(P34R) mutation drives BRAF-inhibitor resistance in a papillary thyroid cancer patient. Conference. Playa Portero, PR.
- 2017. ETV5, an ETS family Transcription Factor, Drives Epithelial-to Mesenchymal Transition through expression of TWIST1 in Papillary Thyroid Cancer. Conference. Victoria, CA.
- 2017. BRAF Mutant Papillary Thyroid Cancer Cells with Concurrent Mutations Along the KRAS-RAC1 Axis Develop Resistance to BRAF(V600E)-Inhibitors and Are Associated with Increases in EMT Markers. Conference. Victoria, CA.
- 2017. Circulating BRAFV600E cell-free DNA detected by droplet digital PCR (ddPCR) as a biomarker in the management of anaplastic thyroid carcinoma (ATC) patients. Conference. Victoria, CA.
- 2017. Pembrolizumab added to Kinase Inhibitor (KI) therapy in Anaplastic Thyroid Carcinoma (ATC): A Single Cancer Center’s Experience. Conference. Victoria, CA.
- 2016. Regulation of CYP26B1 expression in Sertoli cells. Conference. Rio Grande, PR.
- 2016. Regulation of GDNF expression by Sertoli cells. Conference. Saint Malo, FR.
- 2016. Rapamycin inhibits antidepressant effects of leucine in lipopolysaccharide-treated mice. Conference. Brighton, GB.
- 2015. Understanding Acquired Braf Inhibitor Resistance In Braf(V600e) Mutated Thyroid Cancers. Conference. Placencia, BZ.
- 2015. Regulation of the Testis Stem Cell Niche by NOTCH Signaling. Conference. Athens, GR.
- 2015. Regulation of GDNF Expression by NOTCH signaling. Conference. San Juan, PR.
- 2014. Regulation of Germ Line Stem Cell Homeostasis. Conference. Campinas, BR.
- 2014. Mechanisms Controlling the Male Germ Line Stem Cell Niche. Conference. Iguaçu Falls, BR.
- 2013. Regulation of GDNF signaling in the perinatal male germ cell niche. Conference. St John, AG.
- 2013. Effects of activated estrogen receptors on acquired BRAF inhibitor resistance in papillary thyroid cancer (PTC). Conference. San Juan, PR.
- 2013. Estrogens and Thyroid Cancer. Conference. Nairobi, KE.
- 2013. Regulation of the male germline stem cell niche. Conference. Hong Kong, CN.
- 2012. NOTCH signaling in perinatal Sertoli cells modulates germ cell fate. Conference. Rodney Bay, LC.
- 2012. Notch signaling in Sertoli cells controls early germ cell differentiation. Conference. Kyoto, JP.
- 2011. Characterization and in-vitro propagation of canine stem/progenitor spermatogonia. Conference. Montreal, CA.
- 2011. The spermatogonial stem cell niche is not dependent on Leydig cells in the collared peccary (Tayassu tacaju). Conference. Montreal, CA.
- 2011. A role for Notch signaling at male germ cell meiosis?. Conference. Montreal, CA.
- 2010. Role of the bHLH transcription factor HEYL in male germ cell meiosis. Conference. Providenciales, GB.
- 2010. Investigation of Potential Specific Markers for Spermatogonial Stem Cells in the Nile Tilapia (Oreochromis niloticus). Conference. Águas de São Pedro, BR.
- 2010. Delta-like homolog I (Dlk1) is a novel marker for prepubertal Sertoli cells. Conference. Águas de São Pedro, BR.
- 2010. Human spermatogonial stem cells. Conference. Copenhagen, DK.
- 2009. Molecular Mechanisms Regulating Spermatogonial Stem Cells Within their Niche. Conference. Aguas de Lindóia, BR.
- 2009. Differentiation of Spermatogonial Stem Cells into Prostate and Other Somatic Tissues. Conference. São Paulo, BR.
- 2009. Alteration of Signaling Pathways in Spermatogonial Stem Cells by Environmental Toxicants. Conference. São Paulo, BR.
- 2009. Regulation of Spermatogonial Stem Cells Homing and Retention. Conference. Giessen, DE.
- 2008. Toxicity of Silver Nanoparticles in Male Germ-line Stem Cells. Conference. St Maarten, NL.
- 2008. Spermatogonial Stem cells In and Out of Their Niche. Conference. Sao Paulo, BR.
- 2008. Regulation of the Spermatogonial Stem cell Niche. Conference. Budapest, HU.
- 2007. Role of Notch-1 Signaling in the Mammalian Male Germ Line. Conference. Tamarindo, CR.
- 2005. Signaling pathways in germ-lime stem cells. Conference. Asilomar Conference Grounds, US.
- 2004. Role of glial cell line-derived neurotrophic factor (GDNF) in germ-line stem cell fate. Conference. Montego Bay, JM.
- 2001. Isolation of murine testis stem cells based on cell surface phenotype. Conference. Punta Cana, DO.
- 2000. Characterization of Immortalized Germ Cells and Sertoli Cells Using the GFRα-Receptor Family of Proteins. Conference. Punta Cana, DO.
- 1992. The Use of Oncogenes to Immortalize Testicular Cells. Conference. Copenhagen, DK.
Formal Peers
- 2024. Genetic Mutations in Thyroid Cancers. Houston, Texas, US.
- 2023. Molecular Biology of Thyroid Cancer. Houston, Texas, US.
- 2023. Genetic Mutations in Thyroid Cancers. Houston, Texas, US.
- 2023. Novel Combination Therapies for Anaplastic Thyroid Cancer___ Preclinical Studies. Houston, Texas, US.
- 2023. Role of p38 in anaplastic thyroid cancers. Houston, Texas, US.
- 2022. Role of BHC80/LSD1 in spermatogenesis. Invited. Role of BHC80/LSD1 in spermatogenesis. Pullman, WA, US.
- 2022. Genetic Mutations in Thyroid Cancers. Visiting. Genetic Mutations in Thyroid Cancers. Houston, TX, US.
- 2021. Resistance to Kinase Inhibitor Therapies in Thyroid Cancers. Invited. Resistance to Kinase Inhibitor Therapies in Thyroid Cancers. Oxford, OH, US.
- 2021. Genetic Mutations in Thyroid Cancers. Visiting. Genetic Mutations in Thyroid Cancers. Houston, TX, US.
- 2021. Mechanisms of Resistance to Kinase Inhibitors in Anaplastic Thyroid Carcinoma. Visiting. Mechanisms of Resistance to Kinase Inhibitors in Anaplastic Thyroid Carcinoma. Houston, TX, US.
- 2020. A Novel Acquired RAC1 (P34R) mutation induces ATP progression in a PTC patient. Invited. A Novel Acquired RAC1 (P34R) mutation induces ATP progression in a PTC patient. online meeting, OH, US.
- 2020. Acquired BRAF inhibitor resistance in a PTC patient: role of a RAC1 (P34R) mutation. Visiting. Acquired BRAF inhibitor resistance in a PTC patient: role of a RAC1 (P34R) mutation. Houston, TX, US.
- 2020. Genetic Mutations in Thyroid Cancers. Visiting. Genetic Mutations in Thyroid Cancers. Houston, TX, US.
- 2020. Cancer Treatments and Male Fertility. Visiting. Cancer Treatments and Male Fertility. Houston, TX, US.
- 2020. Role of the Epigenetic Reader BHC80 in Development and Disease. Visiting. Role of the Epigenetic Reader BHC80 in Development and Disease. Houston, TX, US.
- 2020. Studying the function of BHC80 in Sertoli cells: using a novel technique for floxing mice. Visiting. Studying the function of BHC80 in Sertoli cells: using a novel technique for floxing mice. Houston, TX, US.
- 2019. Mechanisms of Resistance to Kinase Inhibitors in Anaplastic Thyroid Cancers. Invited. Mechanisms of Resistance to Kinase Inhibitors in Anaplastic Thyroid Cancers. Houston, TX, US.
- 2019. Mechanisms of Resistance to Kinase Inhibitors in PTC/ATC: An Update. Visiting. Mechanisms of Resistance to Kinase Inhibitors in PTC/ATC: An Update. Houston, TX, US.
- 2019. Acquired BRAF inhibitor resistance in a PTC patient: characterization of a RAC1 (P34R) mutation. Invited. Acquired BRAF inhibitor resistance in a PTC patient: characterization of a RAC1 (P34R) mutation. Columbus, OH, US.
- 2018. Mechanisms of Resistance to Kinase Inhibitors in Thyroid Cancers. Visiting. Mechanisms of Resistance to Kinase Inhibitors in Thyroid Cancers. Houston, TX, US.
- 2018. Molecular Biology of Differentiated Thyroid Cancers. Visiting. Molecular Biology of Differentiated Thyroid Cancers. Houston, TX, US.
- 2018. Role of BHC80 Within the Spermatogonial Stem Cell Niche. Visiting. Role of BHC80 Within the Spermatogonial Stem Cell Niche. Houston, TX, US.
- 2018. Molecular Biology of Differentiated Thyroid Cancers. Visiting. Molecular Biology of Differentiated Thyroid Cancers. Houston, TX, US.
- 2017. New Insights Into the Testicular Stem Cell Niche. Invited. New Insights Into the Testicular Stem Cell Niche. Houston, TX, US.
- 2017. The Spermatogonial Stem Cell Niche. Visiting. The Spermatogonial Stem Cell Niche. Houston, TX, US.
- 2016. Notch Signaling in Sertoli Cells. Visiting. Notch Signaling in Sertoli Cells. Houston, TX, US.
- 2015. Mechanisms of Drug Resistance in Papillary Thyroid Cancer. Invited. Mechanisms of Drug Resistance in Papillary Thyroid Cancer. Lubbock, TX, US.
- 2015. Spermatogonial Stem Cell Homeostasis. Invited. Spermtogonial Stem Cell Homeostasis. Washington, DC, DC, US.
- 2014. Effects of Phthalates on Male Germ Line Stem Cells. Invited. Effects of Phthalates on Male Germ Line Stem Cells. Sao Paulo, SP, BR.
- 2014. NOTCH signaling in the male germ line stem cell niche. Invited. NOTCH signaling in the male germ line stem cell niche. San Antonio, TX, US.
- 2012. Plasticity of Spermatogonial Stem Cells: Influence of the Extracellular Matrix. Visiting. Plasticity of Spermatogonial Stem Cells: Influence of the Extracellular Matrix. Houston, TX, US.
- 2012. Cancer stem cells: Current Status and Evolving Complexities. Visiting. Cancer stem cells: Current Status and Evolving Complexities. Houston, TX, US.
- 2012. Testis Stem Cells: An Alternate Source of Pluripotent Stem Cells for Tissue Engineering. Visiting. Testis Stem Cells: An Alternate Source of Pluripotent Stem Cells for Tissue Engineering. Houston, TX, US.
- 2011. Spermatogonial stem cells inside and out: intrinsic and extrinsic control of self-renewal and differentiation. Invited. Spermatogonial stem cells inside and out: intrinsic and extrinsic control of self-renewal and differentiation. Houston, TX, US.
- 2011. Toxicity of Silver Nanoparticles in Male Germ-line Stem Cells. Visiting. Toxicity of Silver Nanoparticles in Male Germ-line Stem Cells. Calgary, CA.
- 2011. Spermatogonial stem cells for in vitro vasculogenesis. Invited. Spermatogonial stem cells for in vitro vasculogenesis. Calgary, CA.
- 2010. Stem cell models for vasculogenesis in 3D scaffolds. Invited. Stem cell models for vasculogenesis in 3D scaffolds. Urbana, IL, US.
- 2010. Spermatogonial Stem Cells For Blood Vessels Regeneration and Engineering. Invited. Spermatogonial Stem Cells For Blood Vessels Regeneration and Engineering. Urbana, IL, US.
- 2010. Using Spermatogonial Stem Cells for Tissue Regeneration. Visiting. Using Spermatogonial Stem Cells for Tissue Regeneration. Urbana, IL, US.
- 2009. Spermatogonial Stem Cells for Tissue Engineering. Invited. Spermatogonial Stem Cells for Tissue Engineering. Belo Horizonte, Minas Gerais, BR.
- 2009. The Spermatogonial Stem Cell Niche. Invited. The Spermatogonial Stem Cell Niche. Urbana, IL, US.
- 2008. Reprogramming Spermatogonial Stem Cells for Capillary Engineering. Invited. Reprogramming Spermatogonial Stem Cells for Capillary Engineering. Urbana, IL, US.
- 2008. Engineering the Spermatogonial Stem Cell Niche. Invited. Engineering the Spermatogonial Stem Cell Niche. Belo Horizonte, BR.
- 2007. Cellular Interactions Within the Spermatogonial Stem Cell Niche. Invited. Cellular Interactions Within the Spermatogonial Stem Cell Niche. Kennett Square, PA, US.
- 2007. The Fate of Spermatogonial Stem Cells. Visiting. The Fate of Spermatogonial Stem Cells. Urbana, IL, US.
- 2007. Spermatogonial Stem Cell Niche and Plasticity. Visiting. Spermatogonial Stem Cell Niche and Plasticity. Urbana, IL, US.
- 2006. Stem cell renewal and carcinogenesis. Visiting. Stem cell renewal and carcinogenesis. Urbana, IL, US.
- 2006. Role of GDNF in spermatogonial stem cell fate. Invited. Role of GDNF in spermatogonial stem cell fate. Washington, DC, US.
- 2006. Nanoparticles for the modulation of signaling pathways. Invited. Nanoparticles for the modulation of signaling pathways. Bethesda, MD, US.
- 2006. Spermatogonial stem cells. Invited. Spermatogonial stem cells. Urbana, IL, US.
- 2006. GDNF signaling in male germ-line stem cells. Invited. GDNF signaling in male germ-line stem cells. Houston, TX, US.
- 2005. Germ-line stem cells: are they potential targets for chemical toxicants?. Invited. Germ-line stem cells: are they potential targets for chemical toxicants?. Urbana, IL, US.
- 2004. GDNF acts through the activation of Src kinase in male germ line stem cells. Invited. GDNF acts through the activation of Src kinase in male germ line stem cells. Washington, DC, US.
- 2003. Self-renewal and differentiation of spermatogonial stem cells in vitro. Invited. Self-renewal and differentiation of spermatogonial stem cells in vitro. Research Triangle Park, NC, US.
- 2002. Differentiation potential of murine testis stem cells in vitro. Invited. Differentiation potential of murine testis stem cells in vitro. Bethesda, MD, US.
- 2001. Proliferation and Differentiation of Bone Marrow Osteogenic Cells. Invited. Proliferation and Differentiation of Bone Marrow Osteogenic Cells. Washington, DC, US.
- 1999. In vitro Osteogenesis by Bone-Marrow-Derived Stem Cells. Invited. In vitro Osteogenesis by Bone-Marrow-Derived Stem Cells. La Jolla, CA, US.
- 1999. Immortalization by Gene Transfection. Invited. Immortalization by Gene Transfection. Urbana, IL, US.
- 1996. Development of an in vitro Model for Mammalian Spermatogenesis and Testis Morphogenesis. Invited. Development of an in vitro Model for Mammalian Spermatogenesis and Testis Morphogenesis. Dayton, OH, US.
- 1993. Apoptosis and Spermatogenesis. Invited. Apoptosis and Spermatogenesis. Copenhagen, DK.
- 1992. A Mouse Model for Spermatogenesis in vitro. Invited. A Mouse Model for Spermatogenesis in vitro. Zürich, CH.
Grant & Contract Support
| Date: | 2024 - Present |
| Title: | Exploring nsPFA ablation therapy for anaplastic thyroid cancer |
| Funding Source: | Philanthropy |
| Role: | Co-PI |
| Date: | 2024 - 2029 |
| Title: | Hormonal Regulation of Sertoli Cell Maturation (subcontract) |
| Funding Source: | NIH-NICHD |
| Role: | Co-I |
| ID: | R01HD010808 |
| Date: | 2024 - 2016 |
| Title: | Role of histone demethylase RIOX1 in DNA repair and response to therapy in medullary thyroid cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2024 - 2029 |
| Title: | Identification of an immune-related prognostic signature in anaplastic thyroid cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2024 - 2029 |
| Title: | Role of p38/MAPK14 in aggressive thyroid cancers |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Date: | 2024 - Present |
| Title: | A Concept Study for Treating Anaplastic Thyroid with Radio-Immunotherapy |
| Funding Source: | Philanthropy |
| Role: | Co-PI |
| Date: | 2023 - 2024 |
| Title: | Genomic Instability in Tumors Resistant to Targeted Therapies |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | ATC: gender disparity, immune landscape and targeted immunotherapy approaches |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2023 - 2028 |
| Title: | Role of p38/MAPK14 in aggressive thyroid cancers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | VD—PTC Research Endocrine. Harnessing CAFs for Therapy |
| Funding Source: | Philanthropy |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | RA220221 Novel combination therapies for anaplastic thyroid cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | RA220221 |
| Date: | 2023 - 2026 |
| Title: | RA220228 Targeting histone demethylase RIOX1 in medullary thyroid cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| Date: | 2023 - 2028 |
| Title: | Hormonal Regulation of Sertoli Cell Maturation (subcontract) |
| Funding Source: | NHI NICHD |
| Role: | Co-I |
| Date: | 2023 - 2025 |
| Title: | Role of the LSD1/BHC80 Complex in Sertoli Cells |
| Funding Source: | NHI NICHD |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | Novel targeted combination treatment strategies for aggressive thyroid cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2021 - 2022 |
| Title: | Overcoming drug resistance in anaplastic thyroid cancer |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | Effective treatment strategies using novel combination therapies in aggressive thyroid cancers |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | Molecular Mechanism of Drug Resistance in Aggressive Thyroid Cancer |
| Funding Source: | Welch Foundation |
| Role: | PI |
| Date: | 2021 - Present |
| Title: | Targeted Therapy Combined with Pembrolizumab in Anaplastic Thyroid Cancer: Predicting and Monitoring Treatment Response |
| Funding Source: | GATEWAY FOR CANCER RESEARCH |
| Role: | Co-I |
| Date: | 2021 - 2023 |
| Title: | Epigenetic Regulation of Testicular Cancers |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Date: | 2020 - Present |
| Title: | The Anaplastic Thyroid Cancer Multidisciplinary Petrick Research Funds |
| Funding Source: | Petrick/MDA funds |
| Role: | Co-Program Leader |
| Date: | 2020 - 2022 |
| Title: | Modulation of the Anaplastic Thyroid Cancer Environment |
| Funding Source: | MDACC IRG |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Pleiotropic roles of RBPJ in Sertoli cells |
| Funding Source: | NIH/NICHD |
| Role: | Principal Investigator-MDACC |
| Date: | 2020 - 2025 |
| Title: | Mechanisms of thyroid cancer progression |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Date: | 2020 - 2022 |
| Title: | Role of BHC80 in Spermatogenesis |
| Funding Source: | NIH/NICHD |
| Role: | PI |
| ID: | R03 HD101650-01 |
| Date: | 2020 - 2022 |
| Title: | Modulation of the Anaplastic Thyroid Cancer Tumor Microenvironment |
| Funding Source: | MD Anderson Cancer Center IRG |
| Role: | PI |
| Date: | 2019 - 2024 |
| Title: | OSU-MDA Thyroid Cancer SPORE- Project 4 |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2019 - 2024 |
| Title: | Retinoic Acid, a Candidate for Male Fertility Preservation After Gonadotoxic Exposure |
| Funding Source: | NIH NICHD |
| Role: | Co-I |
| Date: | 2019 - 2014 |
| Title: | Molecular Regulation of the Perinatal and Adult Male Germ Cell Environment |
| Funding Source: | NIH/NICHD |
| Role: | PI |
| Date: | 2019 - 2010 |
| Title: | Retinoic Acid, a Candidate for Male Fertility Preservation After Cancer Treatment |
| Funding Source: | MDACC IRG |
| Role: | Co-I |
| Date: | 2018 - 2023 |
| Title: | Mechanisms of resistance to combination therapies in anaplastic thyroid cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA233474-01 |
| Date: | 2018 - 2023 |
| Title: | Retinoic Acid, a Candidate for Male Fertility Preservation After Gonadotoxic Exposure |
| Funding Source: | NIH/NICHD |
| Role: | Co-I |
| Date: | 2018 - 2020 |
| Title: | OSU/MDA Thyroid Cancer SPORE Project 4: Mechanisms of resistance to combination therapies in anaplastic thyroid cancer |
| Funding Source: | MDACC Bridge Funding |
| Role: | Co-PI |
| Date: | 2018 - 2023 |
| Title: | The Ohio State University and MD Anderson Cancer Center Thyroid Center SPORE |
| Funding Source: | Ohio State University |
| Role: | Co-Program Leader |
| ID: | 2 P50 CA168505-06 |
| Date: | 2018 - 2019 |
| Title: | Novel Alternative Pathways and Mutational Hotspots in Papillary Thyroid Cancer with Acquired Resistance to BRAF Inhibitors |
| Funding Source: | American Thyroid Association |
| Role: | Mentor |
| Date: | 2018 - 2019 |
| Title: | Retinoic Acid, a Candidate for Male Fertility Preservation After Cancer Treatment |
| Funding Source: | MDACC IRG |
| Role: | Co-I |
| Date: | 2018 - 2020 |
| Title: | Role of BHC80 in Sertoli cells |
| Funding Source: | NIH-NICHD |
| Role: | PI |
| ID: | 1R21HD096557-01 |
| Date: | 2018 - 2021 |
| Title: | MRP: Improving Treatment Strategies for Anaplastic Thyroid Cancer Through Integration of Novel Therapies and Assessment of Treatment Response |
| Funding Source: | UTMDACC |
| Role: | Co-PI |
| Date: | 2018 - 2023 |
| Title: | Role of PAK in Thyroid Cancer (Subcontract) |
| Funding Source: | Ohio State University / NIH / NCI |
| Role: | Co-I |
| ID: | 1R01CA227847-01 |
| Date: | 2018 - 2020 |
| Title: | Novel Genetic and Epigenetic Drivers of Acquired BRAF Inhibitor Resistance in Papillary Thyroid Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2018 - 2021 |
| Title: | Improved Therapies for Anaplastic Thyroid Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2018 - Present |
| Title: | Pharmacodynamic study of vemurafenib in the neoadjuvant setting in patients with locally advanced thyroid cancer |
| Funding Source: | Genentech |
| Role: | Collaborator |
| ID: | PA12-0494 |
| Date: | 2018 - 2018 |
| Title: | Retinoic Acid, a Candidate for Male Fertility Preservation After Cancer Treatment |
| Funding Source: | MDACC IRG |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | Mechanisms of resistance to targeted therapies in papillary thyroid cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2017 - 2018 |
| Title: | Novel pathways to escape targeted therapies in thyroid cancers |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Date: | 2017 - 2020 |
| Title: | MRP: Improving Treatment Strategies for Anaplastic Thyroid Cancer Through Integration of Novel Therapies and Assessment of Treatment Response |
| Funding Source: | MDA |
| Role: | Co-PI |
| Date: | 2017 - 2010 |
| Title: | Preventing Cancer Therapy Toxicities with an Early Stress Reduction Intervention |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Collaborator |
| Date: | 2017 - 2018 |
| Title: | Novel Alternative Pathways and Mutational Hotspots in Papillary Thyroid Cancer with Acquired Resistance to BRAF Inhibitors |
| Funding Source: | American Thyroid Association |
| Role: | Collaborator |
| ID: | ATA-2017-054.R1 |
| Date: | 2017 - 2018 |
| Title: | Role of ETS transcription factors in TERT-mutant thyroid cancers |
| Funding Source: | American Association of University Women |
| Role: | Collaborator |
| Date: | 2017 - 2018 |
| Title: | Mechanisms of Resistance to Targeted Therapies in Papillary Thyroid Cancer |
| Funding Source: | MDACC Bridge Funding |
| Role: | PI |
| ID: | 2017-00054255-Y1 |
| Date: | 2017 - 2022 |
| Title: | Mechanisms of resistance to targeted therapies in papillary thyroid cancers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Mechanisms of resistance to kinase inhibitors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP170124 |
| Date: | 2016 - 2018 |
| Title: | Targeting Anaplastic Thyroid Cancer with Aptamer-Based Therapy |
| Funding Source: | MDACC IRG |
| Role: | PI |
| ID: | 2017-00054242-Y2 |
| Date: | 2016 - 2017 |
| Title: | in vitro and in vivo testing of FSHR agonists in Sertoli cells |
| Funding Source: | Tocopherex |
| Role: | PI |
| Date: | 2016 - 2021 |
| Title: | Deciphering the roles of E2F1 in germ cell maintenance and male fertility |
| Funding Source: | NIH-NICHD |
| Role: | Collaborator |
| ID: | 1 R01-HD084470-A1 |
| Date: | 2015 - 2017 |
| Title: | Targeting Anaplastic Thyroid Cancer with Aptamer-Based Therapy |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Date: | 2015 - 2018 |
| Title: | Immune markers in anaplastic and poorly differentiated thyroid cancer and their clinical significance |
| Funding Source: | Ohio State University / NIH/NCI - CDP Award |
| Role: | Co-I |
| ID: | 5 P50 CA168505-05 |
| Date: | 2015 - 2017 |
| Title: | Improving sperm count in oligospermia |
| Funding Source: | NIH-NICHD |
| Role: | PI |
| ID: | 1R21HD086291-01 |
| Date: | 2015 - 2016 |
| Title: | Assessing the male reproductive toxicity of kinase inhibitors |
| Funding Source: | NIH-NICHD |
| Role: | Other Significant Contributor |
| ID: | 1R03HD086298-01 |
| Date: | 2015 - 2018 |
| Title: | Targeting Anaplastic Thyroid Cancer |
| Funding Source: | Cancer Research Institute (CRI) |
| Role: | Mentor |
| Date: | 2015 - 2019 |
| Title: | Role of ETV5 in BRAF-mutated thyroid cancer and melanoma progression |
| Funding Source: | Daymon-Runyon Cancer Research Foundation |
| Role: | Mentor |
| Date: | 2014 - 2016 |
| Title: | Developmental Research Grant: Role of the Transcription Factor ETV5 in Thyroid Cancer |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | 1 P50 CA168505-01A1 |
| Date: | 2014 - 2021 |
| Title: | Molecular Regulation of the Perinatal Male Germ Cell Niche |
| Funding Source: | NIH-NICHD |
| Role: | PI |
| ID: | R01 HD 081244 |
| Date: | 2014 - 2015 |
| Title: | Novel mechanisms of kinase inhibitors resistance in papillary thyroid cancer |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | PI |
| Date: | 2014 - 2015 |
| Title: | Mechanisms of Mutated BRAF Inhibitor Resistance in Papillary Thyroid Cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Mentor |
| Date: | 2014 - 2017 |
| Title: | NOTCH signaling as a regulator of germ cell fate in the perinatal testis |
| Funding Source: | March of Dimes |
| Role: | PI |
| Date: | 2014 - 2015 |
| Title: | Mechanisms of Resistance to Targeted Therapy in Papillary Thyroid Cancer (PTC) |
| Funding Source: | Mike Hogg Fund |
| Role: | Co-PI |
| Date: | 2014 - 2015 |
| Title: | Mechanisms of Vemurafenib Resistance in BRAF-mutated Papillary Thyroid Cancer (PTC) |
| Funding Source: | Peter Bradley Carlson Charitable Trust |
| Role: | Co-PI |
| Date: | 2014 - 2017 |
| Title: | Mechanisms of acquired resistance to targeted therapies in BRAF V600E mutation-driven human cancers |
| Funding Source: | V-Foundation pre-proposal |
| Role: | Co-PI |
| Date: | 2013 - 2014 |
| Title: | Mechanisms of Vemurafenib Resistance in BRAF-mutated Papillary Thyroid Cancer (PTC) |
| Funding Source: | American Thyroid Association |
| Role: | Co-I |
| Date: | 2013 - 2014 |
| Title: | Mechanisms of acquired resistance to targeted therapies in kinase-driven human cancers: lessons from BRAF-mutated Papillary Thyroid Cancer (PTC) |
| Funding Source: | MDACC/Knowledge Gap RFA |
| Role: | Co-PI |
| Date: | 2012 - 2017 |
| Title: | Signaling crosstalks regulating perinatal male germ cell fate |
| Funding Source: | NIH-NICHD |
| Role: | PI |
| ID: | 1R01HD072771-01 |
| Date: | 2011 - 2015 |
| Title: | Role of HES/HEY family of proteins in mammalian spermatogenesis |
| Funding Source: | NIH-NICHD |
| Role: | PI |
| ID: | 5R21HD068989-02 |
| Date: | 2010 - 2012 |
| Title: | Emergent Behaviors of Integrated Cellular Systems |
| Funding Source: | National Science Foundation (NSF) |
| Role: | Co-I |
| ID: | NSF-FTC |
| Date: | 2007 - 2013 |
| Title: | Isolation and Characterization of Testis Stem Cells; Influence of GDNF |
| Funding Source: | NIH-NICHD |
| Role: | PI |
| ID: | K02-HD054607 |
| Date: | 2005 - 2007 |
| Title: | Real time monitoring of signaling pathways in biological cells |
| Funding Source: | DARPA |
| Role: | Co-PI |
| ID: | SBIR-D2-0449 |
| Date: | 2004 - 2010 |
| Title: | Isolation and characterization of testis stem cells |
| Funding Source: | NIH-NICHD |
| Role: | PI |
| ID: | 5R01HD044543-05 |
| Date: | 2002 - 2003 |
| Title: | Gene Expression Profile of Experimental Seminoma Compared to its Normal Counterpart |
| Funding Source: | Lance Armstrong Foundation |
| Role: | PI |
| Date: | 1998 - 2003 |
| Title: | Long-term Culture of Spermatogonial Stem Cells |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 5R01HD036483-05 |
| Title: | ImpACT: Improving Treatment Strategies for Anaplastic Thyroid Cancer Through Integration of Novel Therapies and Assessment of Tumor Response |
| Funding Source: | NIH-NCI |
| Role: | P01 Co-Leader, Project 1 Principal Investigator, Core B Co-Leader |
| Title: | Roles of p38/MAPK in Anaplastic Thyroid Cancer |
| Funding Source: | CPRIT |
| Role: | PI |
| Title: | Exploring immunotherapy options for lethal anaplastic thyroid cancer |
| Funding Source: | CPRIT |
| Role: | Co-I |
| Title: | Preservation of Fertility in Male Cancer Patients by Pharmacological Approach |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Title: | Targeted Therapy Combined with Pembrolizumab in Anaplastic Thyroid Cancer: Predicting and Monitoring Treatment Response |
| Funding Source: | GATEWAY for Cancer Research |
| Role: | Co-I |
| Title: | Mechanisms of anaplastic thyroid cancer bone metastasis and effects of combinatorial therapies with bone-targeted treatments |
| Funding Source: | Department of Defense |
| Role: | Co-I |
Patient Reviews
CV information above last modified March 03, 2025